How effective is lvosidenib?

The median OS of ivonib is 10.3 months, which is better than the published literature of chemotherapy and other targeted drugs in patients with advanced biliary tract cancer. The median OS of patients with advanced biliary cancer is about 6 months. The 12month survival rate of ivonibgroup was 43%. Tibsovois the first oral small molecule inhibitor of isocitrate dehydrogenase1 (IDH1)mutations. On 20225 month25 day, FDA approved ivonib(TiB sovo;Servier)Expands indications for elderly patients with newly diagnosed IDH1mutant acute myeloid leukemia(AML) or patients with comorbidities to include combination with azacitidine. If you want to get more high-quality information, you can contact Yaodede. Yaode will do its best to learn more about high-quality overseas drugs for you.